Category: Dolutegravir

BLOG: We want dolutegravir for all, and we want it now
Source: makemedicinesaffordable Author: Othoman Mellouk, Intellectual Property and Access to Medicines Lead at the International Treatment Preparedness Coalition (ITPC). Article first published on the Huffington Post here. We’re calling for a compulsory license on a ‘new’ HIV drug to be...

ITPC MENA IN THE REGIONAL CONSULTATION ON ACCELERATING ACCESS TO THE CONTIUUM OF HIV CARE: FOCUS ON HIV TESTING
Beirut, Lebanon, 12–14 July 2017 By the end of 2015, the estimated number of people living with HIV in the Region had reached 330 000. With a continuously growing epidemic coupled with low coverage of ART, standing at 14% of...

New WHO Guidance Report- Treatment Failure and Drug Resistance
WHO urges action against HIV drug resistance threat 20 JULY 2017 | GENEVA - WHO alerts countries to the increasing trend of resistance to HIV drugs detailed in a report based on national surveys conducted in several countries. The Organization warns...

Amendment of the TRIPS Agreement
WTO members on 6 December 2005 approved changes to the WTO’s intellectual property (TRIPS) agreement in order to make permanent a decision on patents and public health originally adopted in 2003. This was formally built into the TRIPS Agreement after...

African Treatment Advocates Call on ViiV Healthcare to Unlock Access to Dolutegravir for North Africa Now
Harare, December 1st, 2015 Today, at the International Conference on AIDS and STIs in Africa (ICASA), treatment advocates and activists from all over Africa united to urge ViiV Healthcare to allow affordable access to an essential drug in four North...

The first Middle East and North Africa Community Advisory Board (MENA-CAB)
Casablanca, Morocco, 28 June-01 July 2014 Despite the fact that HIV prevalence in the countries of the Middle East and North Africa is believed to be low at least among the General Population, the rate of increase of new cases...